Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis

Trial Profile

A Phase 2, 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lorecivivint (Primary)
  • Indications Osteoarthritis
  • Focus Therapeutic Use
  • Sponsors Samumed
  • Most Recent Events

    • 13 Nov 2019 Results of pooled analysis from NCT02095548, NCT03122860 and NCT02536833 studies, presented in a Samumed media release.
    • 13 Nov 2019 Accordng to a Samumed media release, results of post hoc analysis from the study, and safety data pooled from this and NCT02095548, NCT02536833 studies were presented at the 2019 American College of Rheumatology (ACR) Annual Meeting.
    • 15 Jun 2019 Results (n= 635) of post hoc analysis from a phase 2b trial presented at the 20th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top